Professor | Min Huang | Asia Growth Partners

Name

Min Huang

Contact Information

mhuang@simm.ac.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	University of Chinese Academy of Sciences
Faculty	Medical School
Academic Background & Achievements	2002-09--2007-06 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences 1998-09--2002-06 Bachelor's: China Pharmaceutical University
Work Experience	2013-01~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher 2011-10~2012-12 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher 2011-03~2011-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher 2008-01~2011-02 - Dana-Farber Cancer Institute, Harvard Medical School - Postdoctoral Fellow
Awards	China Young Female Scientist Award (2023): National Level WuXi AppTec Life Chemistry Research Award (2017): Other Shanghai Youth May Fourth Medal (2017): Provincial Level Shanghai Women's Innovation New Star Award and Shanghai 'March 8th Red Banner Holder' (2016): Provincial Level Servier Young Pharmacologist Award (2016): Other Zhongyuan Concord Life Medicine Award for Innovation and Breakthrough (2016): Other Lu Jiaxi Young Talent Award, Chinese Academy of Sciences (2013): Ministerial Level

University/Lab Affiliation and Title

University of Chinese Academy of Sciences

Faculty

Medical School

Academic Background & Achievements

2002-09--2007-06 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
1998-09--2002-06 Bachelor's: China Pharmaceutical University

Work Experience

2013-01~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
2011-10~2012-12 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
2011-03~2011-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher
2008-01~2011-02 - Dana-Farber Cancer Institute, Harvard Medical School - Postdoctoral Fellow

Awards

China Young Female Scientist Award (2023): National Level
WuXi AppTec Life Chemistry Research Award (2017): Other
Shanghai Youth May Fourth Medal (2017): Provincial Level
Shanghai Women's Innovation New Star Award and Shanghai 'March 8th Red Banner Holder' (2016): Provincial Level
Servier Young Pharmacologist Award (2016): Other
Zhongyuan Concord Life Medicine Award for Innovation and Breakthrough (2016): Other
Lu Jiaxi Young Talent Award, Chinese Academy of Sciences (2013): Ministerial Level

Areas of Focus	Tumor Pharmacology Tumor Metabolism Tumor Immunology
Publications	Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer, Min Huang, 2024 Discovery of Novel Drug-like PHGDH Inhibitors to Disrupt Serine Biosynthesis for Cancer Therapy, Min Huang, 2023 Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis, Min Huang, 2022 Metabolic Regulation of CD8(+) T Cells: From Mechanism to Therapy, Min Huang, 2022 NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion, Min Huang, 2022 Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT, Min Huang, 2022 SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors, Min Huang, 2022 Antitumor pharmacological research in the era of personalized medicine, Min Huang, 2022 Discovery of Novel Pyrrolo2,3-dpyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors, Min Huang, 2022 Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer, Min Huang, 2022

Areas of Focus

Tumor Pharmacology
Tumor Metabolism
Tumor Immunology

Publications

Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer, Min Huang, 2024
Discovery of Novel Drug-like PHGDH Inhibitors to Disrupt Serine Biosynthesis for Cancer Therapy, Min Huang, 2023
Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis, Min Huang, 2022
Metabolic Regulation of CD8(+) T Cells: From Mechanism to Therapy, Min Huang, 2022
NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion, Min Huang, 2022
Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT, Min Huang, 2022
SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors, Min Huang, 2022
Antitumor pharmacological research in the era of personalized medicine, Min Huang, 2022
Discovery of Novel Pyrrolo2,3-dpyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors, Min Huang, 2022
Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer, Min Huang, 2022

Cancer Pharmacology Metabolism Immunology Therapy Research Drug Development Oncology Biomarkers Clinical Trials

Jialing Liu - Southern University of Science and Technology

Huan Ren - Southern University of Science and Technology

Jun Tian - Southern University of Science and Technology

View All

Personal Information